Antiplatelet Drug Clinical Trial
Official title:
Phase I Clinical Trial of the Tolerance and Pharmacokinetics of Anfibatide in Health Volunteer
This is a phase 1, dose-escalation, and multidose study, aiming to investigate the tolerability, safety and pharmacokinetics of Anfibatate in healthy subjects. The study is divided into 2 intravenous single groups and 3 continuous administration groups. The dose of Anfibatate from 5 IU/60kg to 7 IU/60kg in intravenous single groups. The dose of Anfibatate from 0.002 IU/kg/h, 0.004 IU/kg/h to 0.008 IU/kg/h in continuous administration groups.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04971356 -
1-month DAPT Plus 5-month Ticagrelor Monotherapy Versus 12-month DAPT in Patients With Drug-coated Balloon
|
N/A | |
Not yet recruiting |
NCT06243133 -
Pair Antiplatelet THerapy in Ischemic Stroke With Intracranial Artery Stenosis
|
Phase 4 | |
Recruiting |
NCT06269432 -
Precise Antiplatelet THerapy Guided by Platelet Aggregation Function in Acute Ischemic STROKE(PATH-STROKE)
|
Phase 4 | |
Recruiting |
NCT05852197 -
Effect of Anticoagulant Drug Intervention on Postoperative MALE and MACE in Patients With PAD
|